Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric S Daar

Showing results (201-210 of 222) with videos related to

Pageof 23
Sort By:
Journal of Neurovirology|May 11, 2011
Regional areas and widths of the midsagittal corpus callosum among HIV-infected patients on stable antiretroviral therapiesDavid F Tate, Mehul Sampat, Jaroslaw Harezlak, et al.
The Journal of Infectious Diseases|February 17, 2026
Impact of COVID-19 Monoclonal Antibody Therapy on Subsequent Vaccine-elicited SARS-CoV-2 Immune ResponsesDavey Smith, Isabelle R Weir, Sydney Ramirez, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 29, 2024
2024 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Management of COVID-19: Anti-SARS-CoV-2 Neutralizing Antibody Pemivibart for Pre-exposure ProphylaxisAdarsh Bhimraj, Yngve Falck-Ytter, Arthur Y Kim, et al.
Annals of Internal Medicine|April 17, 2023
Safety and Efficacy of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies Amubarvimab Plus Romlusevimab in Nonhospitalized Patients With COVID-19Teresa H Evering, Kara W Chew, Mark J Giganti, et al.
Open Forum Infectious Diseases|September 22, 2025
Rapid Elimination of Culturable SARS-CoV-2 With Intramuscular or Intravenous Administration of Antiviral Monoclonal Antibody TherapyRinki Deo, Manish C Choudhary, Owen T Glover, et al.
AIDS (London, England)|March 15, 2024
Impact of antiretroviral therapy during acute or early HIV infection on virologic and immunologic outcomes: results from a multinational clinical trialTrevor A Crowell, Justin Ritz, Lu Zheng, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 20, 2016
Nonnucleoside Reverse-transcriptase Inhibitor- vs Ritonavir-boosted Protease Inhibitor-based Regimens for Initial Treatment of HIV Infection: A Systematic Review and Metaanalysis of Randomized TrialsÁlvaro H Borges, Andreas Lundh, Britta Tendal, et al.
Medrxiv : the Preprint Server for Health Sciences|September 21, 2021
Emergence of SARS-CoV-2 Resistance with Monoclonal Antibody TherapyManish C Choudhary, Kara W Chew, Rinki Deo, et al.
Nature Microbiology|October 27, 2022
Emergence of SARS-CoV-2 escape mutations during Bamlanivimab therapy in a phase II randomized clinical trialManish C Choudhary, Kara W Chew, Rinki Deo, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 22, 2025
2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: VilobelimabNandita Nadig, Adarsh Bhimraj, Kelly Cawcutt, et al.
Pageof 23

Showing results (201-210 of 222) with videos related to

Sort By:
Pageof 23
Journal of Neurovirology|May 11, 2011
Regional areas and widths of the midsagittal corpus callosum among HIV-infected patients on stable antiretroviral therapiesDavid F Tate, Mehul Sampat, Jaroslaw Harezlak, et al.
The Journal of Infectious Diseases|February 17, 2026
Impact of COVID-19 Monoclonal Antibody Therapy on Subsequent Vaccine-elicited SARS-CoV-2 Immune ResponsesDavey Smith, Isabelle R Weir, Sydney Ramirez, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 29, 2024
2024 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Management of COVID-19: Anti-SARS-CoV-2 Neutralizing Antibody Pemivibart for Pre-exposure ProphylaxisAdarsh Bhimraj, Yngve Falck-Ytter, Arthur Y Kim, et al.
Annals of Internal Medicine|April 17, 2023
Safety and Efficacy of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies Amubarvimab Plus Romlusevimab in Nonhospitalized Patients With COVID-19Teresa H Evering, Kara W Chew, Mark J Giganti, et al.
Open Forum Infectious Diseases|September 22, 2025
Rapid Elimination of Culturable SARS-CoV-2 With Intramuscular or Intravenous Administration of Antiviral Monoclonal Antibody TherapyRinki Deo, Manish C Choudhary, Owen T Glover, et al.
AIDS (London, England)|March 15, 2024
Impact of antiretroviral therapy during acute or early HIV infection on virologic and immunologic outcomes: results from a multinational clinical trialTrevor A Crowell, Justin Ritz, Lu Zheng, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 20, 2016
Nonnucleoside Reverse-transcriptase Inhibitor- vs Ritonavir-boosted Protease Inhibitor-based Regimens for Initial Treatment of HIV Infection: A Systematic Review and Metaanalysis of Randomized TrialsÁlvaro H Borges, Andreas Lundh, Britta Tendal, et al.
Medrxiv : the Preprint Server for Health Sciences|September 21, 2021
Emergence of SARS-CoV-2 Resistance with Monoclonal Antibody TherapyManish C Choudhary, Kara W Chew, Rinki Deo, et al.
Nature Microbiology|October 27, 2022
Emergence of SARS-CoV-2 escape mutations during Bamlanivimab therapy in a phase II randomized clinical trialManish C Choudhary, Kara W Chew, Rinki Deo, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 22, 2025
2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: VilobelimabNandita Nadig, Adarsh Bhimraj, Kelly Cawcutt, et al.
Pageof 23